Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Nov 16, 2023
Nov 15, 2023
Nov 07, 2023
Presentations
Events
Nov 11 - Nov 15, 2023
Oct 24 - Oct 27, 2023
Sep 26, 2023 at 9:20 AM EDT
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
|
DEFA14A | Additional proxy soliciting materials - definitive |
|
DEFA14A | Additional proxy soliciting materials - definitive |